22 Aug NexPlasmaGen New Board Member
Montreal / August 21, 2025 – NexPlasmaGen is pleased to announce that Mr. Suman Mallick has joined NexPlasmaGen board!
Suman Mallick is a Managing Director at Keystone National Group, where is the co-head of the Financial Assets practice and manages a portfolio of private credit investments. He is also an angel investor with SWAN (Southwest Angel Network). Previously, he was a Managing Director at Revere Capital, and prior to that, he led the credit risk management and capital markets at Austin based startup Skills Fund until its acquisition by a private equity fund. He has also held various investment professional roles at Fortress Investment Group and Citi. He has a BS in Mathematics & Physics, a MBA in Finance, and a MFA. Prior board experience includes Affiniti, the Austin International School, and French American International School of Portland.
NexPlasmaGen is privileged to benefit from Suman’s financial expertise as the company continue to fund the development and commercialization of its medical technology.
ABOUT NEXPLASMAGEN
NexPlasmaGen is converging the emerging field of cold plasma biotechnology into personalized cancer treatment. We are developing high-precision cold plasma delivery systems with the capability to kill cancer cells while sparing surrounding healthy tissue. NexPlasmaGen’s first application is in the treatment of breast cancer. Its patented cold plasma medical device is used to improve patient outcomes in breast conserving therapy.
Contact
Valérie Léveillé, CEO/Founder
1-514-229-9458, valerie.leveille@nexplasmagen.com, https://nexplasmagen.com/
No Comments